Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis

The Annals of Pharmacotherapy
Ju Yeon RyooBong Kyu Yoo

Abstract

In January 2015, US FDA approved secukinumab, a human interleukin-17A (IL-17A) antagonist, for the treatment of plaque psoriasis. To provide unbiased drug information about the efficacy and safety of secukinumab for the treatment of moderate to severe plaque psoriasis by performing meta-analysis. PubMed and EMBASE database searches were conducted. Among the literatures retrieved, relevant Phase III clinical trials were analyzed. Statistical analysis of the data was performed by RevMan. Four pivotal and three non-pivotal Phase III clinical trials were retrieved. All the trials evaluated the efficacy and safety of secukinumab for the treatment of moderate to severe plaque psoriasis with two co-primary endpoints: proportions of Psoriasis Area and Severity Index (PASI) responders and Investigator's Global Assessment (IGA) responders. The overall odd ratios for proportions of PASI responders and IGA responders in secukinumab-containing arm were 65.6 and 62.5 compared to the placebo arm, respectively. Secukinumab was superior to etanercept resulting in both of the odd ratios being 3.7 compared to the etanercept. Secukinumab was generally well tolerated during the one year trial. However, as with other monoclonal antibody medications,...Continue Reading

References

Sep 17, 2011·Journal of the American Academy of Dermatology·Christine C JacobsonAlexa B Kimball
Jan 8, 2014·Expert Opinion on Pharmacotherapy·Andrea ChiricozziSergio Chimenti
Feb 6, 2014·American Journal of Clinical Dermatology·Laura F SandovalSteven R Feldman
Jun 4, 2014·Pediatric Dermatology·Claudia J Posso-De Los RiosIrene Lara-Corrales
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Aug 15, 2014·European Journal of Dermatology : EJD·Knud KragballeKenneth B Gordon
Sep 23, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·C PaulUNKNOWN JUNCTURE study group
Dec 5, 2014·World Journal of Gastroenterology : WJG·Nynne Nyboe Andersen, Tine Jess
Dec 19, 2014·Expert Opinion on Drug Safety·Carlo SelmiYehuda Shoenfeld
Jan 7, 2015·Manual Therapy·Ann Moore, Gwendolen Jull
Feb 26, 2015·Immunotherapy·Zenas Z N Yiu, Richard B Warren
Apr 29, 2015·World Journal of Hepatology·Lorenzo NosottiFranca Del Nonno
Jul 3, 2015·Lancet·Philip Helliwell, Laura Coates
Aug 21, 2015·Expert Opinion on Investigational Drugs·Molly CampaAlan Menter
Oct 1, 2015·The New England Journal of Medicine·Philip J MeaseUNKNOWN FUTURE 1 Study Group
Oct 18, 2015·The Medical Clinics of North America·Ramin Fathi, April Wang Armstrong

❮ Previous
Next ❯

Citations

May 19, 2016·Expert Opinion on Pharmacotherapy·Alexander Egeberg, Lone Skov
Sep 20, 2018·The Journal of Dermatology·Hideki FujitaUNKNOWN Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of
Oct 3, 2018·The Journal of Dermatological Treatment·G PistoneM R Bongiorno
Feb 12, 2019·Journal of Cutaneous Medicine and Surgery·Charles W LyndeGordon E Searles
Mar 23, 2019·The Journal of Dermatological Treatment·Kevin K WuJashin J Wu
May 3, 2019·Expert Opinion on Drug Safety·Sree S KolliSteven R Feldman
May 30, 2019·American Journal of Clinical Dermatology·Kelsey S FloodAlexa B Kimball
Jul 12, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·J R GeorgakopoulosJ Yeung
Jan 1, 2018·The Journal of Dermatological Treatment·Piergiorgio Malagoli
Feb 26, 2020·SAGE Open Medical Case Reports·Reetesh Bose, Jennifer Beecker
Jan 19, 2018·Therapeutic Advances in Chronic Disease·Jillian FriederAlan Menter
Aug 29, 2019·Expert Review of Clinical Pharmacology·Chuanlan Gu, Junyi Yang
Jul 19, 2019·Scientific Reports·Xiaofei ShiCong-Qiu Chu
Nov 19, 2020·Immunotherapy·Scott H BergSteven R Feldman

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01358578
NCT01365455
NCT01555125
NCT01636687
NCT01406938
NCT01412944
NCT02074982

Software Mentioned

EMBASE
JUNCTURE
RevMan
FIXTURE
FEATURE
SCULPTURE
STATURE

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.